Skip to main content

Table 3 Mean annual costs (SD) in Euros within different levels of SDAI disease activity

From: Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

  Costs resource use Treatment costs Total direct costs Costs sick leave Costs work disability (HCA) Costs work disability (FCA)
REM €828.28 (2,491.24) €539.64 (729.46) €1,367.92 (2,621.94) €1,285.2 (1,502.1) €5,772.8 (3,388.7) €917.5 (538.3)
LDA €1,039.02 (2,561.41) €603.93 (762.06) €1,642.95 (2,644.7) €1,874.2 (2,185.9) €7,186.6 (4,864.9) €1,142.1 (772.8)
MDA/HDA €1,702.39 (3,500.74) €637.85 (748.46) €2,340.24 (3,686.89) €3,291.9 (2,871.3) €10,525.7 (6,129.2) €1,672.5 (973.7)
P value 0.06 0.65 0.05 <0.01 <0.01 <0.01
  1. FCA, friction cost approach; HCA, human capital approach; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease activity; REM, remission.
  2. Treatment costs include patients treated with biologic agents (overall, 36.2%. The distribution among different levels of disease activity was equal: REM, 32.2%; LDA, 36%; MDA/HDA, 39%).